Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.
The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.
Experts explain the challenges patients with HR+/HER- breast cancer face in accessing abemaciclib for treatment and the options available such as patient assistance programs for high co-pays.